x

Posted 03 January, 2024

HARROW, INC. appointed John P. Saharek as new CEO

Nasdaq:HROW appointed new Chief Executive Officer John P. Saharek in a 8-K filed on 03 January, 2024.


  Effective January 2, 2024, Harrow, Inc. (the "Company") appointed John P. Saharek as the President and Chief Executive Officer of the Company's ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of HARROW, INC.
Health Care/Life Sciences • Pharmaceuticals
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Market Cap
$397M
View Company Details
HARROW, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective January 2, 2024, Harrow, Inc. (the "Company") appointed John P. Saharek as the President and Chief Executive Officer of the Company's ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company. Mr. Saharek's annual base salary was adjusted to $450,000 and his target bonus will remain at 50% of his annual base salary. Mr. Saharek will continue to report to Mark L. Baum, Chief Executive Officer and Chairman of the Company.